


AUSTRALIAN UNIT TRUST PORTFOLIO UPDATE

T. Rowe Price Global Impact Equity Fund – S Class

As of 31 January 2024





Portfolio Manager:
Hari Balkrishna
Firm:
2010
Investment Experience:
18 Years

INVESTMENT OBJECTIVE

The Fund's investment objective is to provide long-term capital appreciation through growth in the value of its investments whilst at the same time seeking to have a positive effect on the environment and society by investing in companies whose current or future business activities are expected to generate a positive impact under one of the following three impact pillars ("Impact Pillars"): Climate and resources; Social equity and quality of life; and Sustainable innovation and productivity.

TOP 10 HOLDINGS (%)			Impact	Sub	% of
Company	Country	Industry	Pillar	Pillar	Fund
Eli Lilly and Co	United States	Pharmaceuticals	Improving health	Providing health care solutions	3.5
ASML Holding	Netherlands	Semiconductors & Semiconductor Equipment	Sustainable technology	Innovative software & technology	2.9
New Linde	United States	Chemicals	Reducing GHGs	Decarbonization, carbon capture and sequestration	2.6
Roper Technologies	United States	Industrial Conglomerates	Reducing GHGs	Increasing energy efficiency	2.5
Thermo Fisher Scientific	United States	Life Sciences Tools & Services	Improving health	Providing health care solutions	2.2
Taiwan Semiconductor Manufacturing	Taiwan	Semiconductors & Semiconductor Equipment	Sustainable technology	Innovative software & technology	2.2
UnitedHealth Group	United States	Health Care Providers & Services	Improving health	Providing health care solutions	2.1
Waste Connections	United States	Commercial Services & Supplies	Reducing GHGs	Reducing methane & other GHGs	2.1
Intuitive Surgical	United States	Health Care Equipment & Supplies	Improving health	Providing health care solutions	2.1
Danaher Source: T. Rowe Price use:	United States	Life Sciences Tools & Services Istom Structure for impact pill	Improving health ar and sub-pillar classification.	Providing health care solutions	2.1
Annua					alised

					Ailiualiseu	
PERFORMANCE	One Month	Three Months	Year-to- Date	One Year	Two Years	Since Inception
T. Rowe Price Global Impact Equity Fund – S Class (Net – AUD) ¹	2.93%	11.44%	2.93%	14.47%	2.31%	4.85%
MSCI All Country World ex-Australia Index (net of withholding tax) ²	3.87	10.21	3.87	22.55	5.95	10.10
Value Added (Net) **	-0.94	1.23	-0.94	-8.08	-3.64	-5.25

Past performance is not a reliable indicator of future performance.

Source for performance: T. Rowe Price.

Performance is computed in U.S. dollars and converted to Australian dollars using an exchange rate determined by an independent third party. This material is provided for informational purposes only and is not intended to be investment advice or a recommendation to take any particular investment action. The views and portfolio holdings contained herein are as of date noted on the material and are subject to change without further notice. The specific securities identified and described do not necessarily represent all of the securities purchased, sold, or recommended for the Fund and no assumptions should be made that the securities identified and discussed were or will be profitable.


¹ Net-of-fees performance is based on end-of-month redemption prices after the deduction of fees and expenses and the reinvestment of all distributions. Figures include changes in principal value. Investment return and principal value will vary, and an account may be worth more or less at termination than at inception. For further details, please refer to the Fund's Product Disclosure Statement and Reference Guide which are available from Equity Trustees or TRPAU.

² Index returns shown with reinvestment of dividends after the deduction of withholding taxes.

^{**} The Value Added is shown as the Fund (Net) minus its Index.

POSITIONING BY IMPACT SUB-PILLAR

As of 31 January 2024





Reducing GHGs 23.81%



Promoting Healthy Ecosystems 1.22%



Nurturing Circular Economies


10.63%


28.48%



Enabling Social Equity 21.04%









Numbers may not total due to rounding. Source: T. Rowe Price uses a proprietary custom structure for impact pillar and sub-pillar classification.


Cash weight was 3.06%.

SECTOR AND REGION POSITIONING

T. Rowe Price Global Impact Equity Fund vs. MSCI All Country World Index ex Australia Net

RELATIVE SECTOR WEIGHTS


As of 31 January 2024



- T. Rowe Price Global Impact Equity Fund
- MSCI All Country World ex-Australia Index (net of withholding tax)
- Over/Underweighting

RELATIVE REGION WEIGHTS

As of 31 January 2024



Numbers may not total due to rounding.

T. Rowe Price uses the current MSCI/S&P Global Industry Classification Standard (GICS) for sector and industry reporting.

Please see Additional Disclosures page for information about this Global Industry Classification Standard (GICS) information.

Please see Additional Disclosures page for information about this MSCI Information.

COUNTRY DIVERSIFICATION (TOP 10)

	% of Fund	MSCI All Country World ex-Australia Index (net of withholding tax)
United States	55.3	64.1
Canada	5.1	2.9
Japan	4.7	5.7
India	4.4	1.8
Netherlands	4.3	1.2
Taiwan	3.4	1.7
United Kingdom	2.7	3.6
Switzerland	2.5	2.5
France	2.5	2.9
Indonesia	2.1	0.2

MARKET REVIEW

In the early days of the month, U.S. equities struggled as strong economic data prompted investors to temper their expectations for aggressive Federal Reserve (Fed) interest rate cuts in 2024. As the month progressed, shares were lifted by generally favorable corporate earnings and by renewed investor interest in companies expected to benefit from artificial intelligence. However, stocks tumbled on the last day of the month, as Fed policymakers held short-term interest rates steady and gave no indications that they were on the verge of reducing rates.

The European Central Bank (ECB) left its key deposit rate at a record high of 4%, as expected. A more dovish outlook on the economy and a softer tone to comments by ECB President Christine Lagarde raised hopes of a shift to easier policy. She re-emphasised that policy would continue to depend on incoming economic and financial data.

Japanese equities had a strong start to 2024, continuing the strong performance seen last year. The monetary policy backdrop remained highly accommodative—and investors were forced to reassess the likelihood that the Bank of Japan would end its negative interest rate policy in the near term as a deadly earthquake struck Japan's Noto Peninsula on 1 January.

Chinese shares slumped as the economy remained sluggish and the property market remained in distress. Late in the month, the Chinese Vice Premier called upon government agencies to take steps to stabilize the market and support listed Chinese companies.

FUND REVIEW

The fund underperformed its benchmark. Li Auto, which develops new energy vehicles (NEVs) that generate lower use-phase emissions than internal combustion engine vehicles, dragged. The Chinese carmaker's shares fell after it announced an expected delay to the launch of its flagship family multi-purpose vehicle. On the positive front, the company said that the total number of vehicles it delivered in 2023 more than doubled. Leading European contract research organization Evotec was another laggard. The firm's outsourcing model helps pharmaceutical and biotechnology companies reduce fixed costs, mitigate risks, and accelerate innovation. Its shares were weak after news of the current chief executive officer stepping down for personal reasons. In contrast, ASML was a top contributor to relative returns. The semiconductor capital equipment company generates positive impact through its lithography equipment, which is needed to manufacture leading-edge chips with superior energy efficiency. It reported record-high orders in the fourth quarter of 2023. Eli Lilly, whose product portfolio helps consumers manage diabetes and address obesity, also added value. The biopharmaceutical company's shares rallied in anticipation of an earnings beat-following strong performance last year on the successful launch of its diabetes drug Mounjaro and a robust pipeline for indications like Alzheimer's disease and obesity.

PORTFOLIO CHARACTERISTICS

	Fund	MSCI All Country World ex-Australia Index (net of withholding tax)
Number of Issuers	65	2,782
Top 20 Issuers as Percent of Total	43.1%	26.1%
Percent of Portfolio in Cash	3.1%	-
Portfolio Turnover (12 Months)	54.7%	-
Active Share	92.4%	-

OUTLOOK

Entering 2024, we are excited about the market and macroeconomic set-up and believe it will benefit stock pickers.

First, we will be looking at identifying and adding exposure to end-markets with bottoming earnings such as life sciences tools companies (Danaher, Thermo Fisher Scientific), semiconductor capital equipment firms (ASML, TSMC) and freight (Canada National Railway).

Secondly, although we do not allocate to regions, we believe growth in 2024 will be more inclusive toward emerging markets (EM) and, therefore, are making sure we are aware of regional disparities. Our stance toward US equities is broadly neutral as valuations appear full and higher interest rates might pressure companies with a higher cost structure. We are slightly overweight EM (mainly through our EM financial bets). EM are attractively valued relative to developed markets, in our view, and the possibility of incremental fiscal and monetary stimulus generally is likely to be more supportive for EM.

Thirdly, accessing idiosyncratic impact opportunities. For example, companies that are neutral to rising rates, such as SPIE, a leading independent multi-technical services provider in Europe, which helps reduce emissions through energy efficiency improvement projects or select companies exposed to obesity treatment, or GLP-1 innovation, which stands to have a knock-on effect on several industries such as medical technology (Stryker) and nutrition (DSM-Firmenich).

CONTACT US

For more information about the Fund, please contact our Relationship Management team on 02 8667 5700 or visit www.troweprice.com

FUND INFORMATION

Minimum Investment Amount	\$50,000 AUD
APIR	ETL2575AU
ARSN	647 796 478
ISIN	AU60ETL25755
Inception Date	29-Mar-2021
Benchmark	MSCI All Country World ex-Australia Index (net of withholding tax)
Management Fees and Costs*	1.25% p.a.
Distribution	Annually
Buy/Sell	Buy +0.10% / Sell -0.10%

^{*} The Management Fee for the T. Rowe Price Global Impact Equity Fund - S Class is 1.25% p.a. and the Indirect Cost is 0.00% p.a. Full details of other fees and charges are available within the Fund's Product Disclosure Statement and Reference Guide.

ADDITIONAL DISCLOSURES

Unless indicated otherwise the source of all data is T. Rowe Price.

Active Share is a holdings-based measure of active management representing the percentage of a portfolio's holdings that differ from those in its benchmark. Compared with tracking error, which measures the standard deviation of the difference in a manager's returns versus the index returns, Active Share allows investors to get a clearer understanding of what a manager is doing to drive performance, rather than drawing conclusions from observed returns. The greater the difference between the asset composition of a product and its benchmark, the greater the active share is.

Source for MSCI data: MSCI. MSCI and its affiliates and third party sources and providers (collectively, "MSCI") makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indices or any securities or financial products. This report is not approved, reviewed, or produced by MSCI. Historical MSCI data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

The information shown does not reflect any ETFs that may be held in the fund.

Source for Sector Diversification: T. Rowe Price uses the current MSCI/S&P Global Industry Classification Standard (GICS) for sector and industry reporting.

The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of Morgan Stanley Capital International Inc, ("MSCI") and Standard & Poor's, a division of The McGraw-Hill Companies, Inc. ("S&P") and is licensed for use by T. Rowe Price. Neither MSCI, S&P nor any third party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any or such standard or classification, Without limiting any or the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

Certain numbers in this report may not equal stated totals due to rounding. Unless otherwise stated, all data is as of the report production date.

IMPORTANT INFORMATION

Equity Trustees Limited ("Equity Trustees") (ABN 46 004 031 298 AFSL 240975) is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Stock Exchange (ASX:EQT). Equity Trustees and T. Rowe Price Australia Limited ("TRPAU") (ABN: 13 620 668 895 and AFSL: 503741) are, respectively, the responsible entity and investment manager of the T. Rowe Price Australian Unit Trusts.

A Target Market Determination for each T. Rowe Price Australian Unit Trust (or class of units in a Trust) is available here (www.eqt.com.au/insto [eqt.com.au]). It describes who the financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where Equity Trustees Limited, the responsible entity of the T. Rowe Price Australian Unit Trusts may need to review the Target Market Determination for the financial product.

Past performance is not a reliable indicator of future performance. The price of any fund may go up or down. Investment involves risk including a possible loss to the principal amount invested. For general information purposes only, does not take into account the investment objectives, financial situation or needs of any particular investor. For further details, please refer to each fund's product disclosure statement and reference guide which are available from Equity Trustees (www.eqt.com.au/insto) and TRPAU (www.troweprice.com.au/investor).

Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources' accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date noted on the material and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.

This document has been prepared without taking account of any person's individual objectives, financial situation or needs. A person should, before making any investment decisions, consider the appropriateness of the information in this document and seek independent professional advice having regard to their objectives, financial situation and needs.

Any person should consider the relevant product disclosure statement ("PDS") in relation to the fund(s) named in this document (if any) before making a decision in relation to the relevant product. Contact Equity Trustees Limited, the responsible entity and T. Rowe Price Australia Limited, the investment manager, for a copy of the PDS.

© 2024 T. Rowe Price. All Rights Reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE, and the Bighorn Sheep design are, collectively and/ or apart, trademarks of T. Rowe Price Group, Inc.

202402-3365183 202402-3365185